EX-FILING FEES 4 d772361dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107.1

Form S-8

(Form Type)

VIRIDIAN THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

               
Security Type   

Security

Class

Title(1)

  Fee
Calculation
Rule
 

Amount

Registered(1)

 

Proposed

Maximum

Offering

Price Per
Share

 

Maximum

Aggregate

Offering Price

 

Fee

Rate

 

Amount of

Registration
Fee

               
Equity   Common Stock, $0.01 par value per share, to be issued under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan (the “2016 ESPP Plan”)   Other(2)   539,861   $18.37(2)   $9,914,548(2)   $147.60 per $1,000,000   $1,463.39
               
Equity   Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on September 1, 2023   Other(3)   31,000   $19.11(3)   $592,410   $147.60 per $1,000,000   $87.44
               
Equity   Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on September 1, 2023   Other(3)   75,000   $19.11(3)   $1,433,250   $147.60 per $1,000,000   $211.55
               
Equity   Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on October 30, 2023   Other(3)   1,259,400   $13.02(3)   $16,397,388   $147.60 per $1,000,000   $2,420.25
               
Equity   Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on October 30, 2023   Other(3)   474,400   $13.02(3)   $6,176,688   $147.60 per $1,000,000   $911.68
               
Equity   Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on October 30, 2023   Other(3)   206,200   $13.02(3)   $2,684,724   $147.60 per $1,000,000   $396.27
               
Equity   Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on October 30, 2023   Other(3)   62,000   $13.02(3)   $807,240   $147.60 per $1,000,000   $119.15
               
Equity   Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on November 1, 2023   Other(3)   62,000   $12.60(3)   $781,200   $147.60 per $1,000,000   $115.31
               
Equity   Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on January 2, 2024   Other(3)   62,000   $22.35(3)   $1,385,700   $147.60 per $1,000,000   $204.53
               
Equity   Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award granted on February 1, 2024   Other(3)   30,000   $20.00(3)   $600,000   $147.60 per $1,000,000   $88.56
         
Total Offering Amounts     $40,773,148     $6,018.13
         
Total Fee Offsets         $0.00
         
Net Fee Due               $6,018.13

 

(1)

Represents (i) 539,861 shares of common stock of Viridian Therapeutics, Inc. (the “Registrant”) issuable through the 2016 ESPP Plan; (ii) 2,262,000 shares of common stock of the Company issuable pursuant to the Stock Option Inducement Awards granted on September 1, 2023, October 30, 2023, November 1, 2023, January 2, 2024 and February 1, 2024. Pursuant to Rule 416 of the Securities Act of 1933 (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”), also includes additional shares of common stock of the Registrant in respect of the securities identified in the above table that may become issuable through the 2016 ESPP Plan and the Stock Option Inducement Awards as a result of any stock dividend, stock split, recapitalization or other similar transactions.

(2)

Estimated solely for calculating the registration fee, pursuant to paragraphs (c) and (h) of Rule 457 under the Securities Act, on the basis of the average of the high and low sale prices of the shares of common stock of the Company on The Nasdaq Capital Market on February 23, 2024, within five business days prior to filing.

(3)

Based on the exercise price on the date of grant.